Goldman Sachs
AURA icon

Goldman Sachs’s Aura Biosciences AURA Stock Holding History

Goldman Sachs’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.3M Buy
464,668
+285,942
+160% +$2.05M ﹤0.01% 4260
2026
Q1 		$1.2M Buy
178,726
+38,800
+28% +$223K ﹤0.01% 4969
2025
Q4 		$763K Sell
139,926
-55,017
-28% -$327K ﹤0.01% 5319
2025
Q3 		$1.2M Sell
194,943
-17,355
-8% -$113K ﹤0.01% 4896
2025
Q2 		$1.33M Buy
212,298
+90,654
+75% +$530K ﹤0.01% 4498
2025
Q1 		$713K Sell
121,644
-32,410
-21% -$245K ﹤0.01% 4943
2024
Q4 		$1.27M Buy
154,054
+40,082
+35% +$377K ﹤0.01% 4649
2024
Q3 		$1.02M Sell
113,972
-915,949
-89% -$7.85M ﹤0.01% 4622
2024
Q2 		$7.79M Buy
1,029,921
+33,278
+3% +$244K ﹤0.01% 2747
2024
Q1 		$7.82M Sell
996,643
-40,656
-4% -$337K ﹤0.01% 2704
2023
Q4 		$9.19M Buy
1,037,299
+44,097
+4% +$373K ﹤0.01% 2611
2023
Q3 		$8.91M Sell
993,202
-33,702
-3% -$363K ﹤0.01% 2488
2023
Q2 		$12.7M Buy
1,026,904
+738,406
+256% +$7.89M ﹤0.01% 2225
2023
Q1 		$2.68M Buy
288,498
+82,918
+40% +$861K ﹤0.01% 3617
2022
Q4 		$2.16M Buy
+205,580
New +$2.62M ﹤0.01% 3885

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Goldman Sachs's AURA Position: Q2 2026 in Review

Goldman Sachs increased its Aura Biosciences (AURA) stake by 160% in Q2 2026, buying an estimated $2.05M and bringing the position to 464,668 shares worth $3.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4260.

Goldman Sachs first reported a position in AURA in Q4 2022 and has held it in 15 quarters since. The position peaked at $12.7M in Q2 2023. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Goldman Sachs held 464,668 shares of Aura Biosciences worth $3.3M as of Q2 2026.
  • Goldman Sachs bought 285,942 Aura Biosciences shares in Q2 2026, an estimated $2.05M.
  • Aura Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4260 holding.
  • Goldman Sachs first reported a position in Aura Biosciences in Q4 2022 and has held it in 15 quarters since.
  • Goldman Sachs's Aura Biosciences position peaked at $12.7M in Q2 2023.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.